Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.02157
European Journal of Endocrinology, Vol 154, Issue 6, 777-780
Copyright © 2006 by Society of the European Journal of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krassas, G. E
Right arrow Articles by Wiersinga, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krassas, G. E
Right arrow Articles by Wiersinga, W.

COMMENTARY

Smoking and autoimmune thyroid disease: the plot thickens

Gerasimos E Krassas* and Wilmar Wiersinga1,*

Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Tsimiski 92, Thessaloniki 54622, Greece and 1 Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, The Netherlands

(Correspondence should be addressed to G E Krassas; Email: krassas{at}the.forthnet.gr)

Abstract

New studies have shown that smoking may protect against the development of thyroid peroxidase antibodies, which may result in a decreased risk of Hashimoto’s hypothyroidism (HH), whereas it stimulates the development of Graves’ hyperthyroidism (GH). According to the above-mentioned hypothesis, to stop smoking would decrease the risk of GH but increase the risk of HH. Also, smoking has been identified as one of the risk factors for the development or worsening of eye changes after 131I treatment of GH. Additionally, the outcome of medical treatment of Graves’ ophthalmopathy (GO) is less favourable in smokers as compared to non-smokers. There is concern also about the effect of passive smoking on autoimmune thyroid disease. In a recent study it has been shown that the latter may have a deleterious effect on childhood GO.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al.
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285.
[Full Text] [PDF]


Home page
JNMHome page
A. Iagaru and I. R. McDougall
Treatment of Thyrotoxicosis
J. Nucl. Med., March 1, 2007; 48(3): 379 - 389.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. J. Cawood, P. Moriarty, C. O'Farrelly, and D. O'Shea
Smoking and Thyroid-Associated Ophthalmopathy: A Novel Explanation of the Biological Link
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 59 - 64.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society of the European Journal of Endocrinology.